

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

## Class: Air\_Pollution

### Annotations (2)

- `rdfs:comment` "Abstract Introduction: The second leading cause of lung cancer is air pollution. Air pollution and smoking are synergistic. Air pollution can worsen lung cancer survival. Methods: The Early Detection and Screening Committee of IASLC formed a working group (WG) to better understand issues in air pollution and lung cancer. These included identification of air pollutants, their measurement, and proposed mechanisms of carcinogenesis. The burden of disease and the underlying epidemiologic evidence linking air pollution to lung cancer in individuals who never and ever smoked were summarized to quantify the problem, assess risk prediction models, and develop recommended actions. Results: The number of estimated attributable lung cancer deaths has increased by nearly 30% since 2007 as smoking has decreased and air pollution has increased. In 2013, the International Agency for Research on Cancer (IARC) classified outdoor air pollution and particulate matter with aerodynamic diameter less than 2.5 microns (PM2.5) in outdoor air pollution as carcinogenic to humans (IARC Group 1) and as a cause of lung cancer. Lung cancer risk models reviewed do not include air pollution. Estimation of cumulative exposure to air pollution exposure is complex which poses major challenges with accurately collecting long term exposure to ambient air pollution for incorporation into risk prediction models in clinical practice. Conclusion: Worldwide air pollution levels vary widely, and the exposed populations also differ. Advocacy to lower sources of exposure is important. Health care can lower its environmental footprint, becoming more sustainable and resilient. The IASLC community can engage broadly on this topic. Keywords: air pollution; climate change; lung cancer; lung cancer risk."
- `rdfs:comment` "Outdoor air pollution is a major contributor to the burden of disease worldwide. Most of the global population resides in places where air pollution levels, because of emissions from industry, power generation, transportation, and domestic burning, considerably exceed the World Health Organization's health-based air-quality guidelines. Outdoor air pollution poses an urgent worldwide public health challenge because it is ubiquitous and has numerous serious adverse human health effects, including cancer. Currently, there is substantial evidence from studies of humans and experimental animals as well as mechanistic evidence to support a causal link between outdoor (ambient) air pollution, and especially particulate matter (PM) in outdoor air, with lung cancer incidence and mortality. It is estimated that hundreds of thousands of lung cancer deaths annually worldwide are attributable to PM air pollution. Epidemiological evidence on outdoor air pollution and the risk of other types of cancer, such as bladder cancer or breast cancer, is more limited. Outdoor air pollution may also be associated with poorer cancer survival, although further research is needed. This report presents an overview of outdoor air pollutants, sources, and global levels, as well as a description of epidemiological evidence linking outdoor air pollution with cancer incidence and mortality. Biological mechanisms of air pollution-derived carcinogenesis are also described. This report concludes by summarizing public health/policy recommendations, including multilevel interventions aimed at individual, community, and regional scales. Specific roles for medical and health care communities with regard to prevention and advocacy and recommendations for further research are also described."

### Superclasses (1)

- `Location_LC`

### Disjoints (691)

```
"\Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_\", \"\Afinitor_(Everolimus)\",
\"\Afinitor_Disperz_(Everolimus)_\", \"\Alecensa_(Alectinib)_\", \"\Alimta_(Pemetrexed_Disodium)_\",
\"\Alunbrig_(Brigatinib)_\", \"\Alymsys_(Bevacizumab)_\", \"\Avastin_(Bevacizumab)_\",
\"\Cytarabine_(Cytarabine)_\", \"\Enhertu_(Fam-Trastuzumab_Deruxtecan-nxki)_\",
\"\Etopophos_(Etoposide_Phosphate)_\", \"\Exkivity_(Mobocertinib_Succinate)_\", \"\Gavreto_(Pralsetinib)_\",
\"Gemzar_(Gemcitabine_Hydrochloride)_\", \"\Gilotrif_(Afatinib_Dimaleate)_\",
\"Hycamtin_(Topotecan_Hydrochloride)_\", \"\Imfinzi_(Durvalumab)_\", \"\Imjudo_(Tremelimumab-actl)_\",
\"\Infugem_(Gemcitabine_Hydrochloride)_\", \"\Iressa_(Gefitinib)_\", \"\Keytruda_(Pembrolizumab)_\",
\"Krazati_(Adagrasib)_\", \"\Libtayo_(Cemiplimab-rwlc)_\", \"\Lorbrena_(Lorlatinib)_\",
\"Lumakras_(Sotorasib)_\", \"\Mekinist_(Trametinib_Dimethyl_Sulfoxide)_\", \"\Mvasi_(Bevacizumab)_\",
\"\Opdivo_(Nivolumab)_\", \"\Portrazza_(Necitumumab)_\", \"\Retevmo_(Selpercatinib)_\",
\"Rozlytrek_(Entrectinib)_\", \"\Rybrevant_(Amivantamab-vmjw)_\",
\"Tabrecta_(Capmatinib_Hydrochloride)_\", \"\Tafinlar_(Dabrafenib_Mesylate)_\",
\"Tagrisso_(Osimertinib_Mesylate)_\", \"\Taxotere_(Docetaxel)_\", \"\Tecentriq_(Atezolizumab)_\",
\"Tepmetko_(Tepotinib_Hydrochloride)_\", \"\Trexall_(Methotrexate_Sodium)_\", \"\Vizimpro_(Dacomitinib)_\",
```

'\Xalkori\_(Crizotinib)\_\'', '\Yervoy\_(Ipilimumab)\_\'', '\Zirabev\_(Bevacizumab)\_\'', '\Zykadia\_(Ceritinib)\_\'', 4A\_NSCLC, 4B\_NSCLC, Adagrasib\_, Adherence\_Based\_on\_Socioeconomics\_LC, Adherence\_Factors\_LC, Adverse\_Reactions\_ABRAX, Adverse\_Reactions\_ADAGR, Adverse\_Reactions\_AFATI, Adverse\_Reactions\_AFINI, Adverse\_Reactions\_AFINIT, Adverse\_Reactions\_ALECE, Adverse\_Reactions\_ALIMT, Adverse\_Reactions\_ALUNB, Adverse\_Reactions\_ALYMS, Adverse\_Reactions\_AMIVA, Adverse\_Reactions\_ATEZO, Adverse\_Reactions\_AVAST, Adverse\_Reactions\_BRIGA, Adverse\_Reactions\_CAPMA, Adverse\_Reactions\_CEMIP, Adverse\_Reactions\_CYRAM, Adverse\_Reactions\_DOXOR, Adverse\_Reactions\_DURVA, Adverse\_Reactions\_ENHER, Adverse\_Reactions\_ENTRE, Adverse\_Reactions\_ERLOT, Adverse\_Reactions\_ETOP, Adverse\_Reactions\_ETOPO, Adverse\_Reactions\_EXKIV, Adverse\_Reactions\_GAVRE, Adverse\_Reactions\_GEFIT, Adverse\_Reactions\_GEMZA, Adverse\_Reactions\_GILOT, Adverse\_Reactions\_HYCAM, Adverse\_Reactions\_IMFIN, Adverse\_Reactions\_IMJUD, Adverse\_Reactions\_INFUG, Adverse\_Reactions\_IRESS, Adverse\_Reactions\_KEYTR, Adverse\_Reactions\_KRAZA, Adverse\_Reactions\_LIBTA, Adverse\_Reactions\_LORBR, Adverse\_Reactions\_LUMAK, Adverse\_Reactions\_LURB, Adverse\_Reactions\_MEKIN, Adverse\_Reactions\_METH, Adverse\_Reactions\_MVASI, Adverse\_Reactions\_OPDIV, Adverse\_Reactions\_PORTR, Adverse\_Reactions\_RAMUC, Adverse\_Reactions\_RETEV, Adverse\_Reactions\_ROZLY, Adverse\_Reactions\_RYBRE, Adverse\_Reactions\_SELPE, Adverse\_Reactions\_SOTOR, Adverse\_Reactions\_TABRE, Adverse\_Reactions\_TAFIN, Adverse\_Reactions\_TAGRIS, Adverse\_Reactions\_TAXOT, Adverse\_Reactions\_TECEN, Adverse\_Reactions\_TEPME, Adverse\_Reactions\_TOPO, Adverse\_Reactions\_TRAME, Adverse\_Reactions\_TREME, Adverse\_Reactions\_TREXA, Adverse\_Reactions\_VINOR, Adverse\_Reactions\_VIZIM, Adverse\_Reactions\_XALKO, Adverse\_Reactions\_YERVO, Adverse\_Reactions\_ZIRAB, Adverse\_Reactions\_ZYKAD, Afatinib\_Dimaleate\_, Age, **Air\_Pollution**, Amivantamab-vmjw\_, Atezolizumab\_, Behavioral\_Factors\_LC, Beta\_Carotene\_Supplements\_LC, Bio\_Sensors\_LC, Biological\_Effects\_LC, Breathalyzer\_LC, Breathing\_LC, Brigatinib\_, Capmatinib\_Hydrochloride\_, Causes\_and\_Risks\_LC, Cemiplimab-rwlc\_, Chemical\_Sensors\_LC, Choosing\_Quality\_of\_Life\_-\_Reasons\_People\_Forego\_Treatment, Choosing\_Survival\_-\_Deciding\_to\_Undergo\_Treatment, Clinical\_Factors\_LC, Complications\_LC, Contraindications\_ABRAX, Contraindications\_ADAGR, Contraindications\_AFATI, Contraindications\_AFINI, Contraindications\_AFINIT, Contraindications\_ALECE, Contraindications\_ALIMT, Contraindications\_ALUNB, Contraindications\_ALYMS, Contraindications\_AMIVA, Contraindications\_ATEZO, Contraindications\_AVAST, Contraindications\_BRIGA, Contraindications\_CAPMA, Contraindications\_CEMIP, Contraindications\_CYRAM, Contraindications\_DOXOR, Contraindications\_DURVA, Contraindications\_ENHER, Contraindications\_ENTRE, Contraindications\_ERLOT, Contraindications\_ETOP, Contraindications\_ETOPO, Contraindications\_EXKIV, Contraindications\_GAVRE, Contraindications\_GEFIT, Contraindications\_GEMZA, Contraindications\_GILOT, Contraindications\_HYCAM, Contraindications\_IMFIN, Contraindications\_IMJUD, Contraindications\_INFUG, Contraindications\_IRESS, Contraindications\_KEYTR, Contraindications\_KRAZA, Contraindications\_LIBTA, Contraindications\_LORBR, Contraindications\_LUMAK, Contraindications\_LURB, Contraindications\_MEKIN, Contraindications\_METH, Contraindications\_MVASI, Contraindications\_OPDIV, Contraindications\_PORTR, Contraindications\_RAMUC, Contraindications\_RETEV, Contraindications\_ROZLY, Contraindications\_RYBRE, Contraindications\_SELPE, Contraindications\_SOTOR, Contraindications\_TABRE, Contraindications\_TAFIN, Contraindications\_TAGRIS, Contraindications\_TAXOT, Contraindications\_TECEN, Contraindications\_TEPME, Contraindications\_TOPO, Contraindications\_TRAME, Contraindications\_TREME, Contraindications\_TREXA, Contraindications\_VINOR, Contraindications\_VIZIM, Contraindications\_XALKO, Contraindications\_YERVO, Contraindications\_ZIRAB, Contraindications\_ZYKAD, Cultural\_Beliefs\_and\_Perceptions, Cultural\_LC, Degrees\_of\_Smoking\_LC, Demographic\_Factors\_LC, Diet\_LC, Disparities\_in\_Incidence, Dosage\_and\_Administration\_ABRAX, Dosage\_and\_Administration\_ADAGR, Dosage\_and\_Administration\_AFATI, Dosage\_and\_Administration\_AFINI, Dosage\_and\_Administration\_AFINIT, Dosage\_and\_Administration\_ALECE, Dosage\_and\_Administration\_ALIMT, Dosage\_and\_Administration\_ALUNB, Dosage\_and\_Administration\_ALYMS, Dosage\_and\_Administration\_AMIVA, Dosage\_and\_Administration\_ATEZO, Dosage\_and\_Administration\_AVAST, Dosage\_and\_Administration\_BRIGA, Dosage\_and\_Administration\_CAPMA, Dosage\_and\_Administration\_CEMIP, Dosage\_and\_Administration\_CYRAM, Dosage\_and\_Administration\_DOXOR, Dosage\_and\_Administration\_DURVA, Dosage\_and\_Administration\_ENHER, Dosage\_and\_Administration\_ENTRE, Dosage\_and\_Administration\_ERLOT, Dosage\_and\_Administration\_ETOP, Dosage\_and\_Administration\_ETOPO, Dosage\_and\_Administration\_EXKIV, Dosage\_and\_Administration\_GAVRE, Dosage\_and\_Administration\_GEFIT, Dosage\_and\_Administration\_GEMZA, Dosage\_and\_Administration\_GILOT, Dosage\_and\_Administration\_HYCAM, Dosage\_and\_Administration\_IMFIN, Dosage\_and\_Administration\_IMJUD, Dosage\_and\_Administration\_INFUG, Dosage\_and\_Administration\_IRESS, Dosage\_and\_Administration\_KEYTR, Dosage\_and\_Administration\_KRAZA, Dosage\_and\_Administration\_LIBTA, Dosage\_and\_Administration\_LORBR, Dosage\_and\_Administration\_LUMAK, Dosage\_and\_Administration\_LURB, Dosage\_and\_Administration\_MEKIN, Dosage\_and\_Administration\_METH, Dosage\_and\_Administration\_MVASI, Dosage\_and\_Administration\_OPDIV, Dosage\_and\_Administration\_PORTR, Dosage\_and\_Administration\_RAMUC, Dosage\_and\_Administration\_RETEV, Dosage\_and\_Administration\_ROZLY, Dosage\_and\_Administration\_RYBRE, Dosage\_and\_Administration\_SELPE, Dosage\_and\_Administration\_SOTOR, Dosage\_and\_Administration\_TABRE, Dosage\_and\_Administration\_TAFIN, Dosage\_and\_Administration\_TAGRIS, Dosage\_and\_Administration\_TAXOT, Dosage\_and\_Administration\_TECEN, Dosage\_and\_Administration\_TEPME, Dosage\_and\_Administration\_TOPO, Dosage\_and\_Administration\_TRAME, Dosage\_and\_Administration\_TREME, Dosage\_and\_Administration\_TREXA, Dosage\_and\_Administration\_VINOR, Dosage\_and\_Administration\_VIZIM, Dosage\_and\_Administration\_XALKO, Dosage\_and\_Administration\_YERVO, Dosage\_and\_Administration\_ZIRAB, Dosage\_and\_Administration\_ZYKAD, Dosage\_Forms\_and\_Strengths\_ABRAX, Dosage\_Forms\_and\_Strengths\_ADAGR,

Dosage\_Forms\_and\_Strengths\_AFATI, Dosage\_Forms\_and\_Strengths\_AFINI, Dosage\_Forms\_and\_Strengths\_AFINIT, Dosage\_Forms\_and\_Strengths\_ALECE, Dosage\_Forms\_and\_Strengths\_ALIMT, Dosage\_Forms\_and\_Strengths\_ALUNB, Dosage\_Forms\_and\_Strengths\_ALYMS, Dosage\_Forms\_and\_Strengths\_AMIVA, Dosage\_Forms\_and\_Strengths\_ATEZO, Dosage\_Forms\_and\_Strengths\_AVAST, Dosage\_Forms\_and\_Strengths\_BRIGA, Dosage\_Forms\_and\_Strengths\_CAPMA, Dosage\_Forms\_and\_Strengths\_CEMIP, Dosage\_Forms\_and\_Strengths\_CYRAM, Dosage\_Forms\_and\_Strengths\_DOXOR, Dosage\_Forms\_and\_Strengths\_DURVA, Dosage\_Forms\_and\_Strengths\_ENHER, Dosage\_Forms\_and\_Strengths\_ENTRE, Dosage\_Forms\_and\_Strengths\_ERLOT, Dosage\_Forms\_and\_Strengths\_ETOP, Dosage\_Forms\_and\_Strengths\_ETOPO, Dosage\_Forms\_and\_Strengths\_EXKIV, Dosage\_Forms\_and\_Strengths\_GAVRE, Dosage\_Forms\_and\_Strengths\_GEFIT, Dosage\_Forms\_and\_Strengths\_GEMZA, Dosage\_Forms\_and\_Strengths\_GILOT, Dosage\_Forms\_and\_Strengths\_HYCAM, Dosage\_Forms\_and\_Strengths\_IMFIN, Dosage\_Forms\_and\_Strengths\_IMJUD, Dosage\_Forms\_and\_Strengths\_INFUG, Dosage\_Forms\_and\_Strengths\_IRESS, Dosage\_Forms\_and\_Strengths\_KEYTR, Dosage\_Forms\_and\_Strengths\_KRAZA, Dosage\_Forms\_and\_Strengths\_LIBTA, Dosage\_Forms\_and\_Strengths\_LORBR, Dosage\_Forms\_and\_Strengths\_LUMAK, Dosage\_Forms\_and\_Strengths\_LURB, Dosage\_Forms\_and\_Strengths\_MEKIN, Dosage\_Forms\_and\_Strengths\_METH, Dosage\_Forms\_and\_Strengths\_MVASI, Dosage\_Forms\_and\_Strengths\_OPDIV, Dosage\_Forms\_and\_Strengths\_PORTR, Dosage\_Forms\_and\_Strengths\_RAMUC, Dosage\_Forms\_and\_Strengths\_RETEV, Dosage\_Forms\_and\_Strengths\_ROZLY, Dosage\_Forms\_and\_Strengths\_RYBRE, Dosage\_Forms\_and\_Strengths\_SELPE, Dosage\_Forms\_and\_Strengths\_SOTOR, Dosage\_Forms\_and\_Strengths\_TABRE, Dosage\_Forms\_and\_Strengths\_TAFIN, Dosage\_Forms\_and\_Strengths\_TAGRIS, Dosage\_Forms\_and\_Strengths\_TAXOT, Dosage\_Forms\_and\_Strengths\_TECEN, Dosage\_Forms\_and\_Strengths\_TEPME, Dosage\_Forms\_and\_Strengths\_TOPO, Dosage\_Forms\_and\_Strengths\_TRAME, Dosage\_Forms\_and\_Strengths\_TREME, Dosage\_Forms\_and\_Strengths\_TREXA, Dosage\_Forms\_and\_Strengths\_VINOR, Dosage\_Forms\_and\_Strengths\_VIZIM, Dosage\_Forms\_and\_Strengths\_XALKO, Dosage\_Forms\_and\_Strengths\_YERVO, Dosage\_Forms\_and\_Strengths\_ZIRAB, Dosage\_Forms\_and\_Strengths\_ZYKAD, Doxorubicin\_Hydrochloride\_, Drug\_Interactions\_ABRAX, Drug\_Interactions\_ADAGR, Drug\_Interactions\_AFATI, Drug\_Interactions\_AFINI, Drug\_Interactions\_AFINIT, Drug\_Interactions\_ALECE, Drug\_Interactions\_ALIMT, Drug\_Interactions\_ALUNB, Drug\_Interactions\_ALYMS, Drug\_Interactions\_AMIVA, Drug\_Interactions\_ATEZO, Drug\_Interactions\_AVAST, Drug\_Interactions\_BRIGA, Drug\_Interactions\_CAPMA, Drug\_Interactions\_CEMIP, Drug\_Interactions\_CYRAM, Drug\_Interactions\_DOXOR, Drug\_Interactions\_DURVA, Drug\_Interactions\_ENHER, Drug\_Interactions\_ENTRE, Drug\_Interactions\_ERLOT, Drug\_Interactions\_ETOP, Drug\_Interactions\_ETOPO, Drug\_Interactions\_EXKIV, Drug\_Interactions\_GAVRE, Drug\_Interactions\_GEFIT, Drug\_Interactions\_GEMZA, Drug\_Interactions\_GILOT, Drug\_Interactions\_HYCAM, Drug\_Interactions\_IMFIN, Drug\_Interactions\_IMJUD, Drug\_Interactions\_INFUG, Drug\_Interactions\_IRESS, Drug\_Interactions\_KEYTR, Drug\_Interactions\_KRAZA, Drug\_Interactions\_LIBTA, Drug\_Interactions\_LORBR, Drug\_Interactions\_LUMAK, Drug\_Interactions\_LURB, Drug\_Interactions\_MEKIN, Drug\_Interactions\_METH, Drug\_Interactions\_MVASI, Drug\_Interactions\_OPDIV, Drug\_Interactions\_PORTR, Drug\_Interactions\_RAMUC, Drug\_Interactions\_RETEV, Drug\_Interactions\_ROZLY, Drug\_Interactions\_RYBRE, Drug\_Interactions\_SELPE, Drug\_Interactions\_SOTOR, Drug\_Interactions\_TABRE, Drug\_Interactions\_TAFIN, Drug\_Interactions\_TAGRIS, Drug\_Interactions\_TAXOT, Drug\_Interactions\_TECEN, Drug\_Interactions\_TEPME, Drug\_Interactions\_TOPO, Drug\_Interactions\_TRAME, Drug\_Interactions\_TREME, Drug\_Interactions\_TREXA, Drug\_Interactions\_VINOR, Drug\_Interactions\_VIZIM, Drug\_Interactions\_XALKO, Drug\_Interactions\_YERVO, Drug\_Interactions\_ZIRAB, Drug\_Interactions\_ZYKAD, Durvalumab\_, E-Cigarettes\_LC, Electronic\_Sensors\_LC, Emotions\_LC, End\_of\_Life\_Decisions, Entrectinib\_, Enzymatic\_Sensors\_LC, Erlotinib\_Hydrochloride\_, Etoposide\_, Exercise\_LC, Extensive\_Stage\_SCLC, Family\_History\_LC, Gefitinib\_, Genomic\_Sequencing\_LC, Geographical\_Location, Habits\_LC, HIV\_Infection\_LC, Immunosensors\_LC, Increased\_Susceptibility\_LC, Indications\_and\_Usage\_ABRAX, Indications\_and\_Usage\_ADAGR, Indications\_and\_Usage\_AFATI, Indications\_and\_Usage\_AFINI, Indications\_and\_Usage\_AFINIT, Indications\_and\_Usage\_ALECE, Indications\_and\_Usage\_ALIMT, Indications\_and\_Usage\_ALUNB, Indications\_and\_Usage\_ALYMS, Indications\_and\_Usage\_AMIVA, Indications\_and\_Usage\_ATEZO, Indications\_and\_Usage\_AVAST, Indications\_and\_Usage\_BRIGA, Indications\_and\_Usage\_CAPMA, Indications\_and\_Usage\_CEMIP, Indications\_and\_Usage\_CYRAM, Indications\_and\_Usage\_DOXOR, Indications\_and\_Usage\_DURVA, Indications\_and\_Usage\_ENHER, Indications\_and\_Usage\_ENTRE, Indications\_and\_Usage\_ERLOT, Indications\_and\_Usage\_ETOP, Indications\_and\_Usage\_ETOPO, Indications\_and\_Usage\_EXKIV, Indications\_and\_Usage\_GAVRE, Indications\_and\_Usage\_GEFIT, Indications\_and\_Usage\_GEMZA, Indications\_and\_Usage\_GILOT, Indications\_and\_Usage\_HYCAM, Indications\_and\_Usage\_IMFIN, Indications\_and\_Usage\_IMJUD, Indications\_and\_Usage\_INFUG, Indications\_and\_Usage\_IRESS, Indications\_and\_Usage\_KEYTR, Indications\_and\_Usage\_KRAZA, Indications\_and\_Usage\_LIBTA, Indications\_and\_Usage\_LORBR, Indications\_and\_Usage\_LUMAK, Indications\_and\_Usage\_LURB,

Indications\_and\_Usage\_MEKIN, Indications\_and\_Usage\_METH, Indications\_and\_Usage\_MVASI,  
 Indications\_and\_Usage\_OPDIV, Indications\_and\_Usage\_PORTR, Indications\_and\_Usage\_RAMUC,  
 Indications\_and\_Usage\_RETEV, Indications\_and\_Usage\_ROZLY, Indications\_and\_Usage\_RYBRE,  
 Indications\_and\_Usage\_SELPE, Indications\_and\_Usage\_SOTOR, Indications\_and\_Usage\_TABRE,  
 Indications\_and\_Usage\_TAFIN, Indications\_and\_Usage\_TAGRIS, Indications\_and\_Usage\_TAXOT,  
 Indications\_and\_Usage\_TECEN, Indications\_and\_Usage\_TEPME, Indications\_and\_Usage\_TOPO,  
 Indications\_and\_Usage\_TRAME, Indications\_and\_Usage\_TREME, Indications\_and\_Usage\_TREXA,  
 Indications\_and\_Usage\_VINOR, Indications\_and\_Usage\_VIZIM, Indications\_and\_Usage\_XALKO,  
 Indications\_and\_Usage\_YERVO, Indications\_and\_Usage\_ZIRAB, Indications\_and\_Usage\_ZYKAD,  
 Limited\_Stage\_SCLC, Living\_with\_LC\_LC, Lurbinectedin\_, Marijuna\_Smoking\_LC, Medications\_LC,  
 Methotrexate\_Sodium\_, Never-Smokers\_LC, Non-Small\_Cell\_LC, Non-Small\_Cell\_LC\_NSCLC, Non-  
 Small\_Cell\_Lung\_Cancer, Non-Small\_Cell\_Medication\_LC\_, Non-Smokers\_LC, Non-Smokers\_NSCLC, Non-  
 Smokers\_SCLC, Nutrition\_LC, Occupational\_Exposure, Physical\_Activity\_For\_Mitigation\_of\_LC,  
 Physical\_Activity\_For\_Prevention\_Of\_LC, Preventative\_habits\_LC, Quitting/Not\_Smoking\_LC, Racial/Ethnic,  
 Radiation\_Exposure\_LC, Ramucirumab\_, Recurring\_LC\_NSCLC, Recurring\_LC\_SCLC, Rural\_LC, Second-  
 hand\_Smoke\_LC, Secondhand\_Smoke\_LC, Selpercatinib\_, Sensor\_Factors\_LC, Size\_of\_the\_community\_LC,  
 Sleep\_LC, Small\_Cell\_LC, Small\_Cell\_LC\_SCLC, Small\_Cell\_Lung\_Cancer, Small\_Cell\_Medication\_LC\_,  
 Smoke\_LC, Smokers\_LC, Smokers\_NSCLC, Smokers\_SCLC, Smoking\_LC, Smoking\_Marijuana\_LC,  
 Smoking\_Other\_Drugs\_LC, Smoking\_Tobacco\_LC, Socioeconomics\_LC, Sotorasib\_, Stage\_0\_NSCLC,  
 Stage\_1\_NSCLC, Stage\_1\_SCLC, Stage\_2\_NSCLC, Stage\_3A\_NSCLC, Stage\_3B\_NSCLC, Stage\_4\_NSCLC,  
 Support\_Groups\_LC, Symptoms\_and\_Tests\_LC, Symptoms\_NSC, Symptoms\_SC, Tests\_NSC, Tests\_SC,  
 Tobacco\_Smoking, Tobacco\_Smoking\_LC, Topotecan\_Hydrochloride\_, Tramentinib\_Dimethyl\_Sulfoxide,  
 Treatment\_Regimens\_LC, Treatments\_LC, Tremelimumab-actl\_, Urban\_LC,  
 Use\_in\_Specific\_Populations\_ABRAX, Use\_in\_Specific\_Populations\_ADAGR, Use\_in\_Specific\_Populations\_AFATI,  
 Use\_in\_Specific\_Populations\_AFINI, Use\_in\_Specific\_Populations\_AFINIT, Use\_in\_Specific\_Populations\_ALECE,  
 Use\_in\_Specific\_Populations\_ALIMT, Use\_in\_Specific\_Populations\_ALUNB, Use\_in\_Specific\_Populations\_ALYMS,  
 Use\_in\_Specific\_Populations\_AMIVA, Use\_in\_Specific\_Populations\_ATEZO, Use\_in\_Specific\_Populations\_AVAST,  
 Use\_in\_Specific\_Populations\_BRIGA, Use\_in\_Specific\_Populations\_CAPMA, Use\_in\_Specific\_Populations\_CEMIP,  
 Use\_in\_Specific\_Populations\_CYRAM, Use\_in\_Specific\_Populations\_DOXOR,  
 Use\_in\_Specific\_Populations\_DURVA, Use\_in\_Specific\_Populations\_ENHER,  
 Use\_in\_Specific\_Populations\_ENTRE, Use\_in\_Specific\_Populations\_ERLOT, Use\_in\_Specific\_Populations\_ETOP,  
 Use\_in\_Specific\_Populations\_ETOPO, Use\_in\_Specific\_Populations\_EXKIV, Use\_in\_Specific\_Populations\_GAVRE,  
 Use\_in\_Specific\_Populations\_GEFIT, Use\_in\_Specific\_Populations\_GEMZA, Use\_in\_Specific\_Populations\_GILOT,  
 Use\_in\_Specific\_Populations\_HYCAM, Use\_in\_Specific\_Populations\_IMFIN, Use\_in\_Specific\_Populations\_IMJUD,  
 Use\_in\_Specific\_Populations\_INFUG, Use\_in\_Specific\_Populations\_IRESS, Use\_in\_Specific\_Populations\_KEYTR,  
 Use\_in\_Specific\_Populations\_KRAZA, Use\_in\_Specific\_Populations\_LIBTA, Use\_in\_Specific\_Populations\_LORBR,  
 Use\_in\_Specific\_Populations\_LUMAK, Use\_in\_Specific\_Populations\_LURB, Use\_in\_Specific\_Populations\_MEKIN,  
 Use\_in\_Specific\_Populations\_METH, Use\_in\_Specific\_Populations\_MVASI, Use\_in\_Specific\_Populations\_OPDIV,  
 Use\_in\_Specific\_Populations\_PORTR, Use\_in\_Specific\_Populations\_RAMUC, Use\_in\_Specific\_Populations\_RETEV,  
 Use\_in\_Specific\_Populations\_ROZLY, Use\_in\_Specific\_Populations\_RYBRE, Use\_in\_Specific\_Populations\_SELPE,  
 Use\_in\_Specific\_Populations\_SOTOR, Use\_in\_Specific\_Populations\_TABRE, Use\_in\_Specific\_Populations\_TAFIN,  
 Use\_in\_Specific\_Populations\_TAGRIS, Use\_in\_Specific\_Populations\_TAXOT,  
 Use\_in\_Specific\_Populations\_TECEN, Use\_in\_Specific\_Populations\_TEPME, Use\_in\_Specific\_Populations\_TOPO,  
 Use\_in\_Specific\_Populations\_TRAME, Use\_in\_Specific\_Populations\_TREME, Use\_in\_Specific\_Populations\_TREXA,  
 Use\_in\_Specific\_Populations\_VINOR, Use\_in\_Specific\_Populations\_VIZIM, Use\_in\_Specific\_Populations\_XALKO,  
 Use\_in\_Specific\_Populations\_YERVO, Use\_in\_Specific\_Populations\_ZIRAB, Use\_in\_Specific\_Populations\_ZYKAD,  
 Vinorelbine\_Tartrate\_, Warnings\_and\_Precautions\_ABRAX, Warnings\_and\_Precautions\_ADAGR,  
 Warnings\_and\_Precautions\_AFATI, Warnings\_and\_Precautions\_AFINI, Warnings\_and\_Precautions\_AFINIT,  
 Warnings\_and\_Precautions\_ALECE, Warnings\_and\_Precautions\_ALIMT, Warnings\_and\_Precautions\_ALUNB,  
 Warnings\_and\_Precautions\_ALYMS, Warnings\_and\_Precautions\_AMIVA, Warnings\_and\_Precautions\_ATEZO,  
 Warnings\_and\_Precautions\_AVAST, Warnings\_and\_Precautions\_BRIGA, Warnings\_and\_Precautions\_CAPMA,  
 Warnings\_and\_Precautions\_CEMIP, Warnings\_and\_Precautions\_CYRAM, Warnings\_and\_Precautions\_DOXOR,  
 Warnings\_and\_Precautions\_DURVA, Warnings\_and\_Precautions\_ENHER, Warnings\_and\_Precautions\_ENTRE,  
 Warnings\_and\_Precautions\_ERLOT, Warnings\_and\_Precautions\_ETOP, Warnings\_and\_Precautions\_ETOPO,  
 Warnings\_and\_Precautions\_EXKIV, Warnings\_and\_Precautions\_GAVRE, Warnings\_and\_Precautions\_GEFIT,  
 Warnings\_and\_Precautions\_GEMZA, Warnings\_and\_Precautions\_GILOT, Warnings\_and\_Precautions\_HYCAM,  
 Warnings\_and\_Precautions\_IMFIN, Warnings\_and\_Precautions\_IMJUD, Warnings\_and\_Precautions\_INFUG,  
 Warnings\_and\_Precautions\_IRESS, Warnings\_and\_Precautions\_KEYTR, Warnings\_and\_Precautions\_KRAZA,  
 Warnings\_and\_Precautions\_LIBTA, Warnings\_and\_Precautions\_LORBR, Warnings\_and\_Precautions\_LUMAK,  
 Warnings\_and\_Precautions\_LURB, Warnings\_and\_Precautions\_MEKIN, Warnings\_and\_Precautions\_METH,  
 Warnings\_and\_Precautions\_MVASI, Warnings\_and\_Precautions\_OPDIV, Warnings\_and\_Precautions\_PORTR,  
 Warnings\_and\_Precautions\_RAMUC, Warnings\_and\_Precautions\_RETEV, Warnings\_and\_Precautions\_ROZLY,  
 Warnings\_and\_Precautions\_RYBRE, Warnings\_and\_Precautions\_SELPE, Warnings\_and\_Precautions\_SOTOR,  
 Warnings\_and\_Precautions\_TABRE, Warnings\_and\_Precautions\_TAFIN, Warnings\_and\_Precautions\_TAGRIS,  
 Warnings\_and\_Precautions\_TAXOT, Warnings\_and\_Precautions\_TECEN, Warnings\_and\_Precautions\_TEPME,

Warnings\_and\_Precautions\_TOPO, Warnings\_and\_Precautions\_TRAME, Warnings\_and\_Precautions\_TREME, Warnings\_and\_Precautions\_TREXA, Warnings\_and\_Precautions\_VINOR, Warnings\_and\_Precautions\_VIZIM, Warnings\_and\_Precautions\_XALKO, Warnings\_and\_Precautions\_YERVO, Warnings\_and\_Precautions\_ZIRAB, Warnings\_and\_Precautions\_ZYKAD

[OWL HTML inside](#)